Samsung Epis Holdings said in a filing that its subsidiary Samsung Epis Bio signed a commercialization partnership agreement for SB2 and SB4 biosimilars with Teva Pharmaceuticals International GmbH on November 2, 2026, filed on November 3, 2026.

In a filing dated November 3, 2026, Samsung Epis Holdings said its subsidiary Samsung Epis Bio signed a commercialization partnership agreement with Teva for SB2 and SB4 biosimilars on November 2, 2026 (U.S. Eastern Time). The company put the total contract value at up to $420,000,000 (about KRW 563.2 billion), of which the upfront payment is up to $75,000,000 (about KRW 100.6 billion). The company said the agreement is conditional and that the amount and timing of receipts may vary depending on product launch and sales performance, among other factors.

1. 01

   The agreement is a collaboration to commercialize SB2 (a Remicade biosimilar) and SB4 (an Enbrel biosimilar), which Samsung Epis Bio holds.

2. 02

   Samsung Epis Bio is responsible for development, manufacturing and supply, while Teva is responsible for sales of the products in the U.S. market, and profits from commercialization will be shared as set out in the agreement.

3. 03

   The company said the agreement is conditional, that revenue recognition may vary depending on whether the contract conditions are met, and that all or part of the agreement may be terminated if certain events occur.

4. 04

   The company said the contract amount equals about 34% of consolidated revenue of 2025 (KRW 1.67 trillion), and reported the asset ratio as 97.42% based on the separate balance sheet as of the end of 2025.

An AI model translated the Korean summary of this filing into English; every number is carried over from the Korean original. Reference information, not investment advice.

Key figures

Counterparty

Teva Pharmaceuticals International GmbH (Switzerland)

Contract signing date

November 2, 2026 (U.S. Eastern Time, EST)

Maximum contract value

Up to $420,000,000 (about KRW 563.2 billion)Exact amount: Up to $420,000,000 (about KRW 563,200,000,000)

Upfront payment

Up to $75,000,000 (about KRW 100.6 billion)Exact amount: Up to $75,000,000 (about KRW 100,600,000,000)

Launch milestone

Up to $75,000,000 (about KRW 100.6 billion)Exact amount: Up to $75,000,000 (about KRW 100,600,000,000)

Sales milestone

Up to $270,000,000 (about KRW 362.1 billion)Exact amount: Up to $270,000,000 (about KRW 362,100,000,000)

Filing facts

Filing type

Material Management Information

Report name

Material Management Information for Investment Decisions (Subsidiary)

Filed

Nov 3, 2026

Receipt number

20261103800583